Company / Net Income
Edgewise Therapeutics, Inc. Net Income History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$167.8M
FY2025
5-year range
-$167.8M / -$42.8M
FY2021-FY2025
Trend
-25.4%
vs FY2024
Sector context
#142 of 216
Health Care
What the data says
At -$168M, Edgewise Therapeutics, Inc.'s net income ranks #142 of 216 in the Health Care sector. Net Income has declined for 5 consecutive years, from -$17M in FY2020 to -$168M in FY2025.
Based on SEC 10-K filings.
-$168M in FY2025.
Declined from -$100M to -$168M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#142 of 216 in Health CareTop 66% of 216This company -$167.8M Sector average $454.1M
▼
-136.9% below sector average
Key checks
Key Insights
- Edgewise Therapeutics, Inc.'s net income has declined for 5 consecutive years.
- In FY2025, net income decreased 25.4% year-over-year.
- Ranks #142 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.82 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$167.8M | -25.4% |
| FY2024 | -$133.8M | -33.6% |
| FY2023 | -$100.2M | -48.1% |
| FY2022 | -$67.6M | -58.0% |
| FY2021 | -$42.8M | -150.0% |
| FY2020 | -$17.1M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026